Parmax Pharma acquirers lift stake to 58% in ₹35-per-share off-market deal
What's the deal? A consortium led by Dhiren Chandulal Shah and Sunil Chinubhai Shah acquired 1,152,450 shares of Parmax PharmaDealroom has a profile for this one. Try Dealroom → at ₹35 each in an off-market transaction completed on 13 August 2026. The deal lifts the group's combined holding from 27.20% to 58.01%, handing it majority control.
Who's involved? The buyers comprise two primary acquirers and seven persons acting in concert. The shares were purchased from Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani and Pravina Mahasukh Gopani.
Why now? The transaction was executed under a Share Purchase Agreement dated 8 June 2026. The consideration has been paid, though the shares are yet to be credited to the buyers' demat accounts.
The paper trail: Sunil Chinubhai Shah filed the disclosure with BSE Limited under Regulation 18(6) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. All parties were named earlier in the Detailed Public Statement dated 15 June 2026 and the Letter of Offer dated 21 July 2026.
What the numbers show: Crossing the 50% threshold gives the group absolute majority control. The uniform ₹35 price across the block points to a pre-negotiated deal rather than open-market buying.
The signal: The move marks a planned shift in Parmax Pharma's promoter landscape, consolidating ownership firmly in the hands of the Shah-led consortium.
Read more: ScanX News
Image credit: Monash Public Library Service
